EXPO has been a great growth story over the long run. Capital allocation will matter more at this stage of the company's life cycle. The quality is priced in and then some.
Exponent’s revenue has grown at a CAGR of 6% while EBITDA has at 8%. This has been driven by its fantastic business model and industry tailwinds. Exponent provides highly complex consulting services ...
Exponent (Nasdaq:EXPO) hit a new 52-week high Thursday as it is currently trading at $48.08, above its previous 52-week high of $47.93 with 27,392 shares traded as of 10:39 a.m. ET. Average volume has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback